Page 23 - 《中国药科大学学报》2026年第1期

第 57 卷第 1 期 陈方溯，等：2020−2024 年：解锁 “老药新用” 新趋势与新策略 17

drug discovery[J]. Br J Pharmacol, 2011, 162(6): 1239-1249. 100011.
[13] Breckenridge A, Jacob R. Overcoming the legal and regulatory [31] Suzuki S, Kusano C, Horii T, et al. The ideal Helicobacter py-
barriers to drug repurposing[J]. Nat Rev Drug Discov, 2019, lori treatment for the present and the future[J]. Digestion, 2022,
18(1): 1-2. 103(1): 62-68.
[14] Pantziarka P, Vandamme P, Bouche G, et al. On-patent drug re- [32] Sanchez-Burgos L, Navarro-González B, García-Martín S, et al.
purposing: key issues report[EB/OL]. [2025-7-11]. https://www. Activation of the integrated stress response is a vulnerability for
risingtide-foundation.org/wp-content/uploads/2024/02/On- multidrug-resistant FBXW7-deficient cells[J]. EMBO Mol Med,
patent-Drug-Repurposing-White-Paper-02-2024.pdf. 2022, 14(9): e15855.
[15] Jonker AH, O’Connor D, Cavaller-Bellaubi M, et al. Drug re- [33] Riesbeck K, Bredberg A, Forsgren A. Ciprofloxacin does not
purposing for rare: progress and opportunities for the rare dis- inhibit mitochondrial functions but other antibiotics do[J]. An-
ease community[J]. Front Med (Lausanne), 2024, 11: 1352803. timicrob Agents Chemother, 1990, 34(1): 167-169.
[16] Harrison C. Coronavirus puts drug repurposing on the fast [34] Zhang L, Ging NC, Komoda T, et al. Antibiotic susceptibility of
track[J]. Nat Biotechnol, 2020, 38(4): 379-381. mammalian mitochondrial translation[J]. FEBS Lett, 2005,
[17] Xu YC, Liu H, Li JF, et al. Advances in anti-COVID-19 drug 579(28): 6423-6427.
research[J]. China Biotechnol (中国生物工程杂志), 2021, [35] Dong XL, Zheng WF. Emerging technologies for drug repur-
41(6): 111-118. posing: harnessing the potential of text and graph embedding
[18] Gatti M, De Ponti F. Drug repurposing in the COVID-19 era: approaches[J]. Artif Intell Chem, 2024, 2(1): 100060.
insights from case studies showing pharmaceutical [36] Joshi CP, Baldi A, Kumar N, et al. Harnessing network pharma-
peculiarities[J]. Pharmaceutics, 2021, 13(3): 302. cology in drug discovery: an integrated approach[J]. Naunyn
[19] Baron SA, Devaux C, Colson P, et al. Teicoplanin: an alterna- Schmiedebergs Arch Pharmacol, 2025, 398(5): 4689-4703.
tive drug for the treatment of COVID-19[J]? Int J Antimicrob [37] Yıldırım MA, Goh KI, Cusick ME, et al. Drug: target
Agents, 2020, 55(4): 105944. network[J]. Nat Biotechnol, 2007, 25(10): 1119-1126.
[20] De Rosa MC, Purohit R, García-Sosa AT. Drug repurposing: a [38] Liu YF, Zhang SJ, Liu KJ, et al. Advances in drug discovery
nexus of innovation, science, and potential[J]. Sci Rep, 2023, based on network pharmacology and omics technology[J]. Curr
13(1): 17887. Pharm Anal, 2024, 21(1): 33-43.
[21] Padhy BM, Gupta YK. Drug repositioning: re-investigating ex- [39] Lal JC, Mao CS, Zhou YD, et al. Transcriptomics-based net-
isting drugs for new therapeutic indications[J]. J Postgrad Med, work medicine approach identifies metformin as a repurposable
2011, 57(2): 153-160. drug for atrial fibrillation[J]. Cell Rep Med, 2022, 3(10):
[22] Mishra AS, Vasanthan M, Malliappan SP. Drug repurposing: a 100749.
leading strategy for new threats and targets[J]. ACS Pharmacol [40] Reymond JL. Molecular similarity for drug discovery, target
Transl Sci, 2024, 7(4): 915-932. prediction and chemical space visualization[J]. Chimia (Aarau),
[23] Wilkinson GF, Pritchard K. In vitro screening for drug reposi- 2022, 76(12): 1045-1051.
tioning[J]. J Biomol Screen, 2015, 20(2): 167-179. [41] Kumar A, Zhang KYJ. Advances in the development of shape
[24] Khambhati K, Siruka D, Ramakrishna S, et al. Current progress similarity methods and their application in drug discovery[J].
in high-throughput screening for drug repurposing[J]. Prog Mol Front Chem, 2018, 6: 315.
Biol Transl Sci, 2024, 205: 247-257. [42] López-Pérez K, Avellaneda-Tamayo JF, Chen LX, et al. Molec-
[25] Noor F, Junaid M, Almalki AH, et al. Deep learning pipeline for ular similarity: theory, applications, and perspectives[J]. Artif
accelerating virtual screening in drug discovery[J]. Sci Rep, Intell Chem, 2024, 2(2): 100077.
2024, 14(1): 28321. [43] Yan X, Liao CZ, Liu ZH, et al. Chemical structure similarity
[26] Zhao HX, Chen SQ, Cao N, et al. Berberine is a novel mito- search for ligand-based virtual screening: methods and compu-
chondrial calcium uniporter inhibitor that disrupts MCU-EMRE tational resources[J]. Curr Drug Targets, 2016, 17(14): 1580-
assembly[J]. Adv Sci (Weinh), 2025, 12(17): e2412311. 1585.
[27] Zhang MF, Shen YQ. Research progress on pharmacological ef- [44] Li SL, Sun WJ, Li S, et al. Tamsulosin ameliorates bone loss by
-
fects and mechanisms of berberine against Salmonella, Shigella, inhibiting the release of Cl through wedging into an allosteric
Vibrio, Mycobacterium and Klebsiella[J]. Anti-Infect Pharm (抗 site of TMEM16A[J]. Proc Natl Acad Sci USA, 2025, 122(1):
感染药学), 2023, 20(11): 1117-1122. e2407493121.
[28] Monteiro AR, Barbosa DJ, Remião F, et al. Alzheimer’s dis- [45] Umene K, Nagamune T, Kawahara M. Phenotypic screening of
ease: Insights and new prospects in disease pathophysiology, signaling motifs that efficiently induce cell proliferation[J]. Sci
biomarkers and disease-modifying drugs[J]. Biochem Pharma- Rep, 2023, 13(1): 15639.
col, 2023, 211: 115522. [46] Hulkower KI, Herber RL. Cell migration and invasion assays as
[29] Woodward DJ, Thorp JG, Middeldorp CM, et al. Leveraging tools for drug discovery[J]. Pharmaceutics, 2011, 3(1): 107-
pleiotropy for the improved treatment of psychiatric 124.
disorders[J]. Mol Psychiatry, 2025, 30(2): 705-721. [47] Yu PJ, Wang W, Guo WR, et al. Pioglitazone-enhanced brown
[30] Firth A, Prathapan P. Broad-spectrum therapeutics: a new an- fat whitening contributes to weight gain in diet-induced obese
timicrobial class[J]. Curr Res Pharmacol Drug Discov, 2021, 2: mice[J]. Exp Clin Endocrinol Diabetes, 2023, 131(11): 595-